Jifa Zhang[Author] - Search Results

Year	Number of Results
2004	1
2005	1
2008	1
2010	1
2011	2
2014	1
2015	4
2016	1
2017	6
2018	4
2019	3
2020	6
2021	14
2022	26
2023	32
2024	12

1

DYRK1A inhibitors for disease therapy: Current status and perspectives.

Liu T, Wang Y, Wang J, Ren C, Chen H, Zhang J. Liu T, et al. Among authors: zhang j. Eur J Med Chem. 2022 Feb 5;229:114062. doi: 10.1016/j.ejmech.2021.114062. Epub 2021 Dec 21. Eur J Med Chem. 2022. PMID: 34954592 Review.

2

Targeting autophagy-related protein kinases for potential therapeutic purpose.

Xiang H, Zhang J, Lin C, Zhang L, Liu B, Ouyang L. Xiang H, et al. Among authors: zhang j. Acta Pharm Sin B. 2020 Apr;10(4):569-581. doi: 10.1016/j.apsb.2019.10.003. Epub 2019 Oct 18. Acta Pharm Sin B. 2020. PMID: 32322463 Free PMC article. Review.

3

Targeting EZH2 for cancer therapy: From current progress to novel strategies.

Zeng J, Zhang J, Sun Y, Wang J, Ren C, Banerjee S, Ouyang L, Wang Y. Zeng J, et al. Among authors: zhang j. Eur J Med Chem. 2022 Aug 5;238:114419. doi: 10.1016/j.ejmech.2022.114419. Epub 2022 Apr 30. Eur J Med Chem. 2022. PMID: 35569264 Review.

4

Proteolysis-targeting chimeras in breast cancer therapy.

Zhang J, Ouyang L. Zhang J, et al. Future Med Chem. 2020 Dec;12(24):2175-2177. doi: 10.4155/fmc-2020-0279. Epub 2020 Nov 23. Future Med Chem. 2020. PMID: 33225735 Review. No abstract available.

5

Emerging strategies to overcome resistance to third-generation EGFR inhibitors.

Shi K, Wang G, Pei J, Zhang J, Wang J, Ouyang L, Wang Y, Li W. Shi K, et al. Among authors: zhang j. J Hematol Oncol. 2022 Jul 15;15(1):94. doi: 10.1186/s13045-022-01311-6. J Hematol Oncol. 2022. PMID: 35840984 Free PMC article. Review.

6

Targeting epigenetic modifications in Parkinson's disease therapy.

Zhang D, Zhang J, Wang Y, Wang G, Tang P, Liu Y, Zhang Y, Ouyang L. Zhang D, et al. Among authors: zhang j. Med Res Rev. 2023 Sep;43(5):1748-1777. doi: 10.1002/med.21962. Epub 2023 Apr 29. Med Res Rev. 2023. PMID: 37119043 Review.

7

Polo-like Kinase 1 Inhibitors in Human Cancer Therapy: Development and Therapeutic Potential.

Zhang J, Zhang L, Wang J, Ouyang L, Wang Y. Zhang J, et al. J Med Chem. 2022 Aug 11;65(15):10133-10160. doi: 10.1021/acs.jmedchem.2c00614. Epub 2022 Jul 25. J Med Chem. 2022. PMID: 35878418 Review.

8

Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy.

Fang Y, Wang J, Zhao M, Zheng Q, Ren C, Wang Y, Zhang J. Fang Y, et al. Among authors: zhang j. J Med Chem. 2022 Sep 8;65(17):11454-11477. doi: 10.1021/acs.jmedchem.2c00844. Epub 2022 Aug 25. J Med Chem. 2022. PMID: 36006861 Review.

9

Association between inflammatory bowel disease and interleukins, chemokines: a two-sample bidirectional mendelian randomization study.

Fang G, Kong F, Zhang H, Huang B, Zhang J, Zhang X. Fang G, et al. Among authors: zhang j. Front Immunol. 2023 May 9;14:1168188. doi: 10.3389/fimmu.2023.1168188. eCollection 2023. Front Immunol. 2023. PMID: 37228614 Free PMC article.

10

Molecular glues targeting protein degradation pathways for drug discovery.

Ren C, Gan X, Zhou H, Li J, Zhang J. Ren C, et al. Among authors: zhang j. Future Med Chem. 2022 Jan;14(3):135-137. doi: 10.4155/fmc-2021-0229. Epub 2021 Nov 15. Future Med Chem. 2022. PMID: 34779647 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Results by year